195 related articles for article (PubMed ID: 35764144)
1. SUOX and GLUT1 are biomarkers for the prognosis in large duct type intrahepatic cholangiocarcinoma.
Kinjo Y; Naito Y; Akiba J; Sadashima E; Nakayama M; Tanigawa M; Hisaka T; Okabe Y; Yano H
Hum Pathol; 2022 Oct; 128():11-19. PubMed ID: 35764144
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
3. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
4. Preoperative subcategorization based on magnetic resonance imaging in intrahepatic cholangiocarcinoma.
Xiao Y; Zhou C; Ni X; Huang P; Wu F; Yang C; Zeng M
Cancer Imaging; 2023 Feb; 23(1):15. PubMed ID: 36782276
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
[TBL] [Abstract][Full Text] [Related]
6. Development of a Prognostic Score for Cholangiocarcinoma Patients Using a Combination of Biochemical Parameters.
Min-Oo HH; Aung TM; Wongwattanakul M; Maraming P; Proungvitaya T; Proungvitaya S
In Vivo; 2023; 37(3):1145-1155. PubMed ID: 37103102
[TBL] [Abstract][Full Text] [Related]
7. Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity.
Shuang Z; Mao Y; Lin G; Wang J; Huang X; Chen J; Duan F; Li S
Biomed Res Int; 2018; 2018():8182575. PubMed ID: 29682557
[TBL] [Abstract][Full Text] [Related]
8. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
9. Incremental value of volumetric multiparametric MRI over Fudan score for prognosis of unresectable intrahepatic cholangiocarcinoma treated with systemic chemotherapy.
Pandey A; Mohseni A; Shaghaghi M; Pandey P; Rezvani Habibabadi R; Hazhirkarzar B; Ly A; Panid Madani S; Borhani A; Kamel IR
Eur J Radiol; 2024 Jan; 170():111196. PubMed ID: 38029705
[TBL] [Abstract][Full Text] [Related]
10. Analysis of metastasis and survival between extrahepatic and intrahepatic cholangiocarcinoma: A large population-based study.
Liao P; Cao L; Chen H; Pang SZ
Medicine (Baltimore); 2021 Apr; 100(16):e25635. PubMed ID: 33879742
[TBL] [Abstract][Full Text] [Related]
11. Bile duct adenoma may be a precursor lesion of small duct type intrahepatic cholangiocarcinoma.
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2021 Jan; 78(2):310-320. PubMed ID: 33405289
[TBL] [Abstract][Full Text] [Related]
12. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
14. CS-iCCA, A New Clinically Based Staging System for Intrahepatic Cholangiocarcinoma: Establishment and External Validation.
Lozada ME; Zhang N; Jin W; Wongjarupong N; Yang JD; Voss MM; Prasai K; Amakye DO; Harmsen WS; Chaudhary S; Bathe OF; Borad MJ; Patel TC; Gores GJ; Therneau TM; Roberts LR
Am J Gastroenterol; 2023 Dec; 118(12):2173-2183. PubMed ID: 36940423
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
Tang Z; Yang Y; Zhang Q; Liang T
Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
[TBL] [Abstract][Full Text] [Related]
16. Different expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma.
Kubo Y; Aishima S; Tanaka Y; Shindo K; Mizuuchi Y; Abe K; Shirabe K; Maehara Y; Honda H; Oda Y
Hum Pathol; 2014 Aug; 45(8):1610-7. PubMed ID: 24824030
[TBL] [Abstract][Full Text] [Related]
17. Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis.
Takahashi K; Obeid J; Burmeister CS; Bruno DA; Kazimi MM; Yoshida A; Abouljoud MS; Schnickel GT
Ann Transplant; 2016 Apr; 21():208-15. PubMed ID: 27068242
[TBL] [Abstract][Full Text] [Related]
18. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
Sasaki M; Sato Y; Nakanuma Y
Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
[TBL] [Abstract][Full Text] [Related]
19. Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study.
Vasuri F; Deserti M; Corradini AG; Tavolari S; Relli V; Palloni A; Frega G; Curti S; Mattioli S; Cescon M; D'Errico A; Brandi G
Sci Rep; 2023 Feb; 13(1):2580. PubMed ID: 36781903
[TBL] [Abstract][Full Text] [Related]
20. Levels of pretreatment serum lipids predict responses to PD-1 inhibitor treatment in advanced intrahepatic cholangiocarcinoma.
Yang Z; Zhang D; Sima X; Fu Y; Zeng H; Hu Z; Hou J; Pan Y; Zhang Y; Zhou Z; Chen M; Hu D
Int Immunopharmacol; 2023 Feb; 115():109687. PubMed ID: 36628893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
